Qualified sources
Genotyping reports, clinical assessments, participant reports, physiology, and protocol-specified laboratory or imaging data.
Proposed research framework
Follow change.
Follow change.
Preserve authority.
Connect qualified genetic context, longitudinal neurological observations, controlled research analytics, and independent assessment—without collapsing them into one claim.
Platform narrative: INTRINSICA® Research · neurological specification v0.1
GenotypingClinical + phenotypeIndependent endpointsFollow-up over time
01
What it is
A connected framework—not a treatment engine.
A therapeutic-agnostic proposal for bringing qualified genotype–phenotype evidence into study execution while keeping protocol authority, participant support, and independent endpoints distinct.
“A study captures outcomes. Connected research examines the story behind them.”
01
Context
Study genetic information alongside clinical and phenotypic data—not as an independent treatment instruction.
02
Continuity
Connect baseline characterization, repeated observations, treatment exposure, and follow-up.
03
Traceability
Link outputs to sources, qualifications, model versions, protocol purpose, and limitations.
04
Governance
Automate preparation and routing; preserve decisions for authorized investigators and study authorities.
Source basis · INTRINSICA platform narrative; neurological manual §§1–2
02
How it connects
Evidence moves through controlled boundaries.
Each layer has a defined role. Novel exploratory output takes a different route from established source values or protocol-defined safety thresholds.
Controlled analysis
Qualification, pinned models, versioned outputs, uncertainty, and output classification.
Split by class
Permitted content may enter review. Novel Class X content routes to a sealed research store by default.
Study coordination
Review packets, decision records, authorized tasks, participant support, and exception queues.
Independent reference
Protocol-defined endpoints recorded independently after predictions are timestamped.
Consent + disclosure scopeProtocol + configurationMasking + safetyAppend-only lineage
Source basis · neurological manual §§2, 7, 10, 13
03
Research journey
From study lock to bounded claims.
Select a phase to see what the workflow prepares, what must be accepted, and where authority remains.
Source basis · neurological S0–S10 workflow, condensed into six presentation phases
04
Neurological focus
Seven modules. Different questions. Shared discipline.
Every proposed module requires the core genotype panel and longitudinal phenotype. The measurements, independent references, and limitations change with the research question.
Source basis · neurological manual §5; workbook 04_Neuro_Modules
05
Study-design branches
The protocol changes what S7 may do.
“Investigator-initiated” describes leadership—not whether a study assigns an intervention. The study design determines the authorization branch.
Source basis · neurological manual §4; workbook 03_Study_Config and S7
06
Collaboration scope
What a research collaboration could include.
These are proposed workstreams and evidence products—not a representation that every capability is implemented or available for a named study.
Study architecture
Translate an approved protocol into a versioned configuration with module selection, assessment schedule, role permissions, genotype requirements, APOE decision, output register, and independent references.
- Protocol-to-workflow mapping
- Study-specific readiness tracks
- Masking-aware role design
- Defined output permissions
Source readiness
Connect report identity, assay context, provenance, required calls, device metadata, visit windows, and phenotype completeness.
Research analytics
Run locked, prespecified comparisons with source links, version identifiers, qualification state, and explicit limits.
Investigator review + participant follow-up
Assemble permitted review packets, capture investigator decisions, coordinate protocol tasks, reminders, care-partner support where consented, and immediate possible-AE routing.
Separate evidence packages
Prepare distinct analyses for therapeutic effect, measurement validity, workflow utility, and the incremental contribution of genotype.
Source basis · INTRINSICA collaboration pathways; neurological manual §§7, 11, 14
07
Authority boundary
Automate preparation. Not authority.
Human review is necessary, but review alone does not transform an exploratory output into authorized decision support.
Class X exploratory output → sealed store by default → no investigator or participant visibility → no clinical influence
Source basis · neurological manual §§2.1–2.3, 10–12
08
Evidence questions
One framework. Four questions that must not be merged.
Select an evidence question to see what it asks and the interpretive boundary it preserves.
Source basis · INTRINSICA “four separate questions”; neurological manual §14
09
Synthetic workflow simulator
Readiness is not one score.
Choose a synthetic state. Observe how separate tracks prevent an analytical issue from being mistaken for a care, support, or safety instruction.
Source basis · workbook synthetic validation scenarios; no patient, genotype, clinical, or outcome data
10
Research possibilities
Questions worth testing—not benefits presumed.
The framework is designed to make these questions prospectively testable and independently interpretable.
Does context add value?
Compare clinical-only, phenotype-enhanced, core-genotype-enhanced, and disease-extension models against an independent reference.
Who changes—and how?
Study repeated observations, trajectories, response heterogeneity, and recovery patterns without treating a model score as a clinical endpoint.
Does the workflow work?
Evaluate completeness, review, authorized execution, follow-up, exception handling, masking, and provenance as workflow questions.
Can an exploratory output progress?
Only through a prospective evidence package, resolved classification, locked version, defined context of use, permitted responses, and protocol/IRB authorization.
Source basis · INTRINSICA platform questions; neurological manual §§4.4, 14
11
Implementation readiness
Proposed architecture. Open activation dependencies.
At this version, the activation gate remains on hold. The dependencies below must be resolved for a named study; the presentation itself is not evidence that they are complete.
Named host study
Protocol, statistical analysis plan, indication, sponsor responsibilities, and IRB approval.
Qualified laboratory
Named laboratory, assay specification, applicable APOE method, variant reconciliation, and assay-specific acceptance criteria.
Production validation
Computerized-system validation, role and masking tests, e-signature method, access controls, and production audit implementation.
Output governance
Fixed classification register, resolved tier/class conflicts, novel-signal policy, and study-specific visibility permissions.
Study operations
Confirmed instruments, versions, windows, systems of record, integration method, owners, and operational targets.
Data + disclosure terms
Genomic authorization, disclosure policy, privacy controls, secondary-use rights, publication terms, and negative-result reporting.
Not represented
No implemented named study, validated neurological model, regulatory compliance determination, enrollment authorization, product release, or demonstrated clinical benefit.
Not claimed
No diagnosis, disease prediction, direct measurement of brain oxidative stress or neuroinflammation, autonomous prescribing, genotype-directed treatment, or automated device adjustment.
Source basis · neurological manual §§1, 15, 17
Research collaboration
Start with a neurological question that matters.
Discuss a sponsor-led trial, investigator-initiated study, prospective cohort, measurement collaboration, or independent evaluation pathway.